BioAge Therapeutics
BioAge Therapeutics Raises $350M Series C to Transform Healthcare
Quick Facts
BioAge Therapeutics
Longevity biotechnology company developing therapies to reverse cellular aging and extend healthy human lifespan by 50+ years.
About the Funding
BioAge Therapeutics has successfully raised $350M in a Series C funding round, bringing their total valuation to $4.3B. This significant investment will fuel the company's mission to advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies.
Use of Funds
Advance anti-aging drug trials, expand research into age-related diseases, and scale manufacturing for clinical studies
Company Overview
Longevity biotechnology company developing therapies to reverse cellular aging and extend healthy human lifespan by 50+ years.
Key Investors
- • Genentech Ventures
- • Gilead Sciences
- • Andreessen Horowitz Bio Fund
- • Jeff Bezos
Founders
- • Dr. Sarah Longevity
- • Dr. James Youth
Previous Rounds
Market Impact
This funding round positions BioAge Therapeutics as a leader in the Biotech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...